Published in Vaccine Weekly, May 29th, 2002
The company reported a net loss for the period, which totaled $0.7 million, or $0.02 per share on a fully diluted basis. The gross margin earned on product sales increased to $14.1 million, or 34% of total sales in 2002, from $13.6 million, or 23% of total sales, in the first quarter of 2001. This improvement reflects increased sales of Nabi-HB [hepatitis B immune globulin (human)], and improvement in the mix of biopharmaceutical sales and antibody sales.
"We continued to leverage the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly